A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia - 02/09/11
, Evelyn V Hess, MD b, c, James I Hudson, MD, SM c, d, e, Jeffrey A Welge, PhD c, f, Sarah E Berno, BPh a, c, Paul E Keck, MD c, fAbstract |
Purpose |
To assess the efficacy of fluoxetine in the treatment of patients with fibromyalgia.
Subjects and methods |
Sixty outpatients (all women, aged 21–71 years) with fibromyalgia were randomly assigned to receive fluoxetine (10–80 mg/d) or placebo for 12 weeks in a double-blind, parallel-group, flexible-dose study. The primary outcome measures were the Fibromyalgia Impact Questionnaire total score (score range, 0 [no impact] to 80) and pain score (score range, 0–10). Secondary measures included the McGill Pain Questionnaire, change in the number of tender points, and total myalgic score.
Results |
In the intent-to-treat analysis, women who received fluoxetine (mean [± SD] dose, 45 ± 25 mg/d) had significant (P = 0.005) improvement in the Fibromyalgia Impact Questionnaire total score compared with those who received placebo, with a difference of –12 (95% confidence interval [CI]: –19 to –4). They also had significant (P = 0.002) improvement in the Fibromyalgia Impact Questionnaire pain score (difference, –2.2 [95% CI: –3.6 to –0.9]), as well as in the Fibromyalgia Impact Questionnaire fatigue (P = 0.05) and depression (P = 0.01) scores and the McGill Pain Questionnaire (P = 0.01), when compared with subjects who received placebo. Although counts for the number of tender points and total myalgic scores improved more in the fluoxetine group than in the placebo group, these differences were not statistically significant.
Conclusion |
In a 12-week, flexible-dose, placebo-controlled trial, fluoxetine was found to be effective on most outcome measures and generally well tolerated in women with fibromyalgia.
Le texte complet de cet article est disponible en PDF.Keywords : Fibromyalgia, Fluoxetine, Randomized clinical trial, Serotonin reuptake inhibitors
Plan
 | Supported by an investigator-initiated grant from Eli Lilly and Company, Indianapolis, Indiana. |
Vol 112 - N° 3
P. 191-197 - février 2002 Retour au numéro
Article précédent
- Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies
- Melanie Peters, Nikola Jeck, Stephan Reinalter, Andreas Leonhardt, Burkhard Tönshoff, G.ünter Klaus, Martin Konrad, Hannsjörg W Seyberth
- Clinical prediction of deep venous thrombosis using two risk assessment methods in combination with rapid quantitative D-dimer testing
- Jacques Cornuz, William A Ghali, Daniel Hayoz, Rebecca Stoianov, Michèle Depairon, Bertrand Yersin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?